A nurse is giving discharge instructions to a patient who has been ordered Guaifenesin (Mucinex) to take BID for 3 days after discharge. What response by the patient lets her know that he understands how to take his medication?

Status asthmaticus is a severe and potentially life-threatening asthma exacerbation that does not respond well to usual treatment measures. The primary goal in managing status asthmaticus is to relieve the bronchospasm and improve airflow. Short-acting 62-agonists, such as albuterol, are bronchodilators that work quickly to relax the smooth muscles of the airways, providing immediate relief of bronchospasm.

While determining the cause of the acute exacerbation and obtaining a peak flow reading are important aspects of asthma management, in the case of status asthmaticus, the immediate priority is to administer a bronchodilator to alleviate the severe symptoms and improve the child's breathing. Once the acute symptoms are addressed, further assessment and interventions can be carried out to identify the cause and monitor the child's condition.

During an acute asthma attack, the airways become narrowed and inflamed, leading to symptoms such as wheezing, shortness of breath, and chest tightness. Short-acting beta2 agonists like Albuterol are the first-line medication for relieving acute asthma symptoms. They work by quickly relaxing the smooth muscles in the airways, resulting in bronchodilation and improved airflow. Albuterol provides rapid relief of symptoms and is often administered via inhalation.
A. Long-acting beta2 agonists (e.g., salmeterol) are typically used as maintenance therapy for long-term control of asthma symptoms, rather than for immediate relief during an acute attack.
C. Corticosteroids (e.g., fluticasone) are anti-inflammatory medications that are often prescribed for asthma, but they are more commonly used as part of a long-term management plan and may not provide immediate relief during an acute attack.
D. Anticholinergics (e.g., ipratropium) are sometimes used in combination with short-acting beta2 agonists for acute asthma exacerbations, but they are not typically the initial treatment choice for an acute asthma attack.